<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/98A0166A-44D7-44A0-8876-7824EA20BF4B"><gtr:id>98A0166A-44D7-44A0-8876-7824EA20BF4B</gtr:id><gtr:name>School of Biomedical Sciences</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/98A0166A-44D7-44A0-8876-7824EA20BF4B"><gtr:id>98A0166A-44D7-44A0-8876-7824EA20BF4B</gtr:id><gtr:name>School of Biomedical Sciences</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/39EE3945-CDA5-4319-8051-46B34D3B9AA0"><gtr:id>39EE3945-CDA5-4319-8051-46B34D3B9AA0</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:otherNames>Anthony</gtr:otherNames><gtr:surname>Ferguson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/C319ED3B-3BDF-4971-9C99-CEFBEFDD519E"><gtr:id>C319ED3B-3BDF-4971-9C99-CEFBEFDD519E</gtr:id><gtr:firstName>Lynn</gtr:firstName><gtr:surname>Rutkowski</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/7A8330A4-1EC4-41FC-8216-55F6F40B2C58"><gtr:id>7A8330A4-1EC4-41FC-8216-55F6F40B2C58</gtr:id><gtr:firstName>Calum</gtr:firstName><gtr:surname>Sutherland</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0801507"><gtr:id>857ACC57-9F59-4D0D-A3AD-17D5DDABCB1B</gtr:id><gtr:title>Quantitative analysis of key protein phosphorylation events as pathway biomarkers of metabolic disease in human cells.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801507</gtr:grantReference><gtr:abstractText>A combination of a more sedentary lifestyle and diets rich in fat has resulted in an explosion of health problems associated with metabolic dysfunction. For example, there are 2.3 million people in the UK with Type 2 diabetes, while one in ten women of child bearing age will experience polycystic ovarian syndrome. Indeed, simply being overweight increases the chances of developing these diseases. Type 2 diabetes alone costs the NHS around #2 billion pounds per year, while diabetes diagnosis is expected to double in the next 10 years. Type 2 diabetes is a major cause of heart disease, blindness, amputation and stroke, so reduces quality of life for individuals for many years as well as reducing life expectancy by around 10 years. 
One of the key features of Type 2 diabetes is poor response to the hormone insulin. All evidence points to this ?insulin resistance? occurring prior to the development of Type 2 diabetes, but it is technically impossible at present to screen for insulin resistance in the general population. We strongly believe that earlier diagnosis and more targeted therapy would prevent progression to Type 2 diabetes, hence preventing the devastating complications of the disease. In addition, insulin resistance is strongly associated with all obesity related diseases, including polycystic ovarian syndrome, hypertension and fatty liver disease. Therefore the same diagnostic approach, and potentially the same therapy could be applied to all these ?metabolic diseases?.
In this proposal we aim to develop novel methodology (using state-of the-art Mass Spectrometry techniques) to accurately measure multiple biomarkers of insulin action inside cells. Insulin induces modifications of many proteins inside cells, and these modifications do not occur in the same pattern when cells or tissues are insulin resistant. Therefore accurate measurement of these biomarkers gives three things; firstly the pattern of modification after exposure to insulin provides the insulin sensitivity of the cells or tissues, secondly, an abnormal pattern provides the specific location of the molecular defect in the cells or tissues, and finally identification of the molecular defect allows classification of different forms of insulin resistance in order to identify the correct treatment for that subgroup.
The project will be split into two phases, the development of the methodology, and validation of the new methodology using cells and carefully collected muscle biopsies from volunteers with different amounts of body fat (obesity), and therefore a range of different levels of insulin resistance.</gtr:abstractText><gtr:technicalSummary>Loss of regulatory control of intracellular signalling is closely associated with many diseases. For example, reduced insulin signalling is a major characteristic of Type 2 Diabetes Mellitus, which affects the lives of 2.3 million people in the UK, costing the NHS #2 billion a year. Intracellular signalling is mediated, in large part, by reversible posttranslational modification of proteins. Possibly the best characterised is protein phosphorylation. Quantitative assessment of a range of key phosphorylation events would provide biomarkers of the status of the signalling ?network? within cells/tissues. Identification of defective pathways in disease, and importantly the specific pathway component responsible for the defect, would improve understanding of disease mechanisms, and classify metabolic diseases at the molecular level. This would improve therapy selection and confirmation of drug efficacy in trials. The latter is particularly the case with drugs targeting a specific component in a signalling pathway. 

Until recently, only semi-quantitative analysis of such pathways has been possible using techniques such as western blotting and immunohistochemistry. This is also limited by availability and quality of phosphorylation-specific antibodies. However, recent progress in quantitative phosphoproteomics makes the process less comparative and more accurate. In a pilot project, we have developed a LC-MS/MS procedure to quantify the phosphorylation status of the residues responsible for activation of protein kinase B/Akt. This method provides a stiochiometry measurement rather than fold difference between experimental samples. We propose to build on this and develop the technique to rapidly quantify eighteen phosphorylation events, in eight key proteins, as markers of the insulin sensitivity of important signalling networks. This will include key nodes in the PI-3 kinase/Akt pathway, the ERK signalling pathway, proximal events in insulin signalling, and nutrient sensing pathways. Many of these are currently impossible to quantify, primarily due to the quality of available phosphospecific antibodies. Importantly, we will validate the biomarkers in 5 different cell systems, 2 animal models of diabetes, and muscle biopsies from volunteers with variable whole body insulin sensitivity. These biopsies have already been collected and screened for a few pathways using current techniques and so a direct comparison of the new technology can be made. The biomarkers can then be used in the classification of insulin resistant states and the analysis of drug response.</gtr:technicalSummary><gtr:fund><gtr:end>2012-09-27</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-08-10</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>375818</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>School of Biomedical Sciences</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Centre for Neuroregeneration (CNR)</gtr:department><gtr:description>Brain biochemistry of fat feeding</gtr:description><gtr:id>21042139-C517-4E67-BDA1-79A21E1BAA95</gtr:id><gtr:impact>We have transferred the skill of neurovascular imaging from Edinburgh to Dundee. This will complement our current skills base of molecular signalling analysis.

We are preparing a manuscript for publication.</gtr:impact><gtr:partnerContribution>Dr Horsburgh provided the animals and training in neurovascular imaging technology.</gtr:partnerContribution><gtr:piContribution>We analysed blood borne and tissue markers of inflammation in a high fat fed model of hypertension</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Local Diabetes Group</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>E0D3A980-E8B1-4F11-8DB8-75F8C5364A41</gtr:id><gtr:impact>I inform our local diabetes patients group on the progress of local research. I am the main academic contact for the group.

I engage in a two way debate on the key roles for research in helping with diabetes, and also participate in fundraising for diabetes research.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011,2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Conference on AD</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>17DC3494-3C08-4D3F-9AC9-A1C33467CC12</gtr:id><gtr:impact>I organised a 3 day event for over 100 scientists from around the world attended a workshop, seminar series and debate on the good and bad aspects of animal models of Alzheimer's disease.

The biochemical Society published all of the presentations including the debate session. National funding bodies attended the meeting and indicated they would use the information to inform future funding policies</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cafe Science</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>A24F7AD7-AA35-4154-BF14-622EF1715057</gtr:id><gtr:impact>over 100 people attended my presentation on obesity; a public health problem, and the question-answer session went on for over 1 hour. In addition the event was filmed and place on youtube.

I received a burst of interest for participation in human trials, and questions by email on health advice.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public Lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>BCD58ACA-F1BA-430E-8351-16ACE780C47D</gtr:id><gtr:impact>The main outcome is to keep the local community informed on our research efforts, this leads hopefully better educated patients and carers.

We often see increased public donations to our University fundraising, and we see increased enquiries about public involvement in our research programme, and invitations to visit local public groups.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008,2009,2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press interview on type 3 diabetes</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BC16A173-0CB4-4634-A7B7-94A1BFE6DD6A</gtr:id><gtr:impact>I gave an interview to the Daily Mail providing an opinion on the links between diet and dementia.

very recent.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK Project Grant</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Cancer Research UK (CRUK)</gtr:fundingOrg><gtr:id>BC9397B6-46B5-4B83-BB07-C8DD01DFE1C4</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>84649</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Diabetes UK studentship</gtr:description><gtr:end>2013-10-02</gtr:end><gtr:fundingOrg>Diabetes UK</gtr:fundingOrg><gtr:id>64FED841-9ADE-412E-9F18-476E5783B1F4</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Diabetes UK SRAG</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FFD3FBC3-877B-4D52-BA85-E0CFF8DE62EA</gtr:id><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have developed reagents and a protocol to simultaneously assess the phosphorylation stoichiometry of 6 phosphorylation events related to insulin action on cells and in vivo.</gtr:description><gtr:id>4F62AFB4-D515-488C-B69C-51B3E9120C66</gtr:id><gtr:impact>The work to date has been proof of concept and validation. We anticipate it forming the basis of a service for academics and industry with a specific interest in insulin action, including those working on diabetes, obesity, fatty liver disease and polycystic ovarian syndrome.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Quantitative Phosphoproteomics</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have developed and characterised our own antibodies to 5 proteins involved in insulin action.</gtr:description><gtr:id>FB3E3CD5-E580-44DA-AF0F-88825F5D48FF</gtr:id><gtr:impact>The antibodies are of use in the academic study of diabetes, cancer, obesity and neurodegeneration.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>antibodies</gtr:title><gtr:type>Antibody</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have investigated 20 potential biomarkers in isolated human PBMCs as a readout for activity status of GSK3 and potential upstream regulatory molecules. This has led to the generation of a panel of validated assessment tools for GSK3 activity, based around western blot and IP assay but which could be developed into a ELISA method for high throughput screening.</gtr:description><gtr:id>1C68C6E1-510D-4039-B1A2-CC611B21BA36</gtr:id><gtr:impact>The impact will depend on the next stage of the development of the biomarkers, which are being applied to a study where patients have taken the GSK3 inhibitor lithium. Our proposal is that this panel of biomarkers will provide a quantifiable assessment of response to lithium dose, improving the design of lithium trials and the identification of efficacy of lithium in several clinical trials.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Biomarkers lithium</gtr:title><gtr:type>Physiological assessment or outcome measure</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/422FFF61-81B8-4C58-85EC-CEA4C9C40A6C"><gtr:id>422FFF61-81B8-4C58-85EC-CEA4C9C40A6C</gtr:id><gtr:title>Phosphorylation of a splice variant of collapsin response mediator protein 2 in the nucleus of tumour cells links cyclin dependent kinase-5 to oncogenesis.</gtr:title><gtr:parentPublicationTitle>BMC cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/58a71279ec3c6bb3c2e59f58927f5afe"><gtr:id>58a71279ec3c6bb3c2e59f58927f5afe</gtr:id><gtr:otherNames>Grant NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1471-2407</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A6CD54AF-A9AF-4DEE-A655-ABE9710D4934"><gtr:id>A6CD54AF-A9AF-4DEE-A655-ABE9710D4934</gtr:id><gtr:title>Neuronal deletion of GSK3? increases microtubule speed in the growth cone and enhances axon regeneration via CRMP-2 and independently of MAP1B and CLASP2.</gtr:title><gtr:parentPublicationTitle>BMC biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f5a09aaa315d78f2e3af1313ec0b1253"><gtr:id>f5a09aaa315d78f2e3af1313ec0b1253</gtr:id><gtr:otherNames>Liz MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1741-7007</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/74C78557-D8C7-4B4E-A88B-8C9D49876A1C"><gtr:id>74C78557-D8C7-4B4E-A88B-8C9D49876A1C</gtr:id><gtr:title>Dual regulation of transcription factor Nrf2 by Keap1 and by the combined actions of ?-TrCP and GSK-3.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/eb211cd5026e33918b23dc11692346c7"><gtr:id>eb211cd5026e33918b23dc11692346c7</gtr:id><gtr:otherNames>Hayes JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5449FBCB-689C-4892-A8AC-2061241336C4"><gtr:id>5449FBCB-689C-4892-A8AC-2061241336C4</gtr:id><gtr:title>Obesity-induced insulin resistance in human skeletal muscle is characterised by defective activation of p42/p44 MAP kinase.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9f33478c70ceadb7bb0b4bc35634431e"><gtr:id>9f33478c70ceadb7bb0b4bc35634431e</gtr:id><gtr:otherNames>Ruiz-Alcaraz AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/311C6703-5BF4-4689-9784-B9730E334CF8"><gtr:id>311C6703-5BF4-4689-9784-B9730E334CF8</gtr:id><gtr:title>Invited commentary on Lithium treatment and risk for dementia in adults with bipolar disorder.</gtr:title><gtr:parentPublicationTitle>The British journal of psychiatry : the journal of mental science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/908d189a52b38453735b7fd76c626abe"><gtr:id>908d189a52b38453735b7fd76c626abe</gtr:id><gtr:otherNames>Sutherland C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0007-1250</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801507</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>160D22D0-5677-4513-A0AC-7F3526B7F336</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Metabolic and Endocrine</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>